is wegovy a glp 1 drug GLP-1 obesity drugs cleared of suicide warning Novo Nordisk launches its Wegovy
Description
Obesity is a major driver of US health care costs, totaling almost $173 billion annually, according to the CDC in 2024
Cardiovascular disease or diabetes
The ongoing global surge in demand for GLP-1 receptor agonists for both licensed and off-label indications continues to limit their availability in the UK
doi:10.3390/ijms22031296 27
Weight regain following GLP-1 discontinuation occurs gradually but consistently in most patients
Both involve subcutaneous needles, dosing schedules, and pharmacy conversations that sound remarkably similar
